Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00071537" target="_blank" >RIV/00216224:14110/13:00071537 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/13:#0002203 RIV/00209805:_____/13:#0000474
Result on the web
<a href="http://dx.doi.org/10.4149/neo_2013_020" target="_blank" >http://dx.doi.org/10.4149/neo_2013_020</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2013_020" target="_blank" >10.4149/neo_2013_020</a>
Alternative languages
Result language
angličtina
Original language name
Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients
Original language description
Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4Ghomozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used. Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neoplasma
ISSN
0028-2685
e-ISSN
—
Volume of the periodical
60
Issue of the periodical within the volume
2
Country of publishing house
SK - SLOVAKIA
Number of pages
9
Pages from-to
151-159
UT code for WoS article
000320086800005
EID of the result in the Scopus database
—